How well does intranasal semax reach the brain, and how long does it act?

TL;DR

Semax is a synthetic heptapeptide developed in Russia as a fragment analog of ACTH. Its whole clinical identity depends on intranasal delivery: eaten or injected, it performs poorly because it is rapidly degraded. Snorted or delivered as a drop onto the olfactory epithelium, it reaches brain tissue in minutes without passing through the liver. The evidence base is predominantly Russian-language and older; Western peer-reviewed replication is limited. Used at standard protocol doses (300–1200 µg intranasally), it produces measurable acute shifts in attention, mood, and stress tolerance. Chronic effects are proposed via BDNF/NGF induction. The safety record over three decades of Russian clinical use is reasonable but the regulatory and quality landscape for non-Russian buyers is genuinely uneven.

What is semax?

Semax is a 7-amino-acid peptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). It was developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences by Nikolai Myasoedov and colleagues. It corresponds to the N-terminal ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro stabilization motif, which confers resistance to peptidase degradation and extends its half-life relative to native ACTH fragments.

Semax is included in the Russian Vital and Essential Drugs List. It has been used in Russian clinical practice for ischemic stroke, optic nerve disease, ADHD in children, and post-surgical cognitive support. Outside Russia, it is not an approved medication in the US, EU, or UK; Western availability is through research-chemical channels and specialty compounding pharmacies.

Why the intranasal route matters

Most therapeutic peptides face a brutal triad: (1) rapid degradation by gastric and pancreatic proteases, so oral delivery delivers almost nothing systemically; (2) rapid proteolytic clearance in the plasma after injection, so even with high injected doses, exposure duration is short; and (3) the blood-brain barrier (BBB), a tight capillary wall that excludes most peptides from the central nervous system even when plasma levels are high.

Intranasal delivery sidesteps all three problems through a mechanism that was well-characterized only in the last fifteen years. The olfactory epithelium, located high in the nasal cavity, contains olfactory neurons whose axons pass directly through the cribriform plate into the olfactory bulb. The trigeminal nerve provides a secondary route to the brainstem and deeper structures. Peptides deposited onto or near the olfactory epithelium can travel along these neural pathways, bypassing the BBB entirely and reaching brain tissue within minutes.

Standard intranasal drop delivery deposits a large fraction of the dose in the anterior nasal cavity, where it enters systemic circulation via the nasal mucosa but not the olfactory pathway. Devices that reach the olfactory epithelium specifically (designed intranasal atomizers, head-back "drip" technique with a specific delivery volume) increase the nose-to-brain fraction. This is one of the under-discussed reasons for variability in reported semax effects: technique matters.

What is the actual bioavailability to the brain?

Central bioavailability of intranasal semax has been estimated in rodent radiolabel studies at 60–70% of the administered dose, with peak cerebrospinal fluid concentrations occurring 3–10 minutes after delivery. Plasma half-life is 15–25 minutes. Urinary elimination is rapid; most is cleared within 90 minutes.

Crucially, the pharmacodynamic half-life outlasts the pharmacokinetic half-life by orders of magnitude. Semax induces BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) mRNA expression in the hippocampus and prefrontal cortex, with protein-level effects observable 24 hours or more after a single dose. This is the mechanism most proposed for the persistent cognitive effects users and researchers describe after the acute plasma window has closed.

Compared to alternative routes:

• Oral: under 5% of dose reaches plasma; near-zero reaches brain.
• Subcutaneous injection: 80–100% plasma bioavailability, but BBB crossing is minimal — most of the dose is cleared without reaching the CNS.
• Intranasal (general): 25–40% central bioavailability with standard technique.
• Intranasal (olfactory-targeted): 60–70% central bioavailability.

What does the clinical evidence actually show?

This is where transparency matters. Most published trials are Russian-language and predate current Western reporting standards.

Stroke / cerebrovascular disease. Semax is approved in Russia for acute ischemic stroke treatment. Multiple randomized trials (Gusev, Skvortsova, and colleagues, 2005 onward) report reduced mortality and improved NIHSS recovery at 300–1200 µg/day intranasal during the first 10 days post-stroke. Sample sizes range from 50 to 200 patients. These trials are not registered in ClinicalTrials.gov and not replicated by Western groups.

ADHD in children. Russian open-label and small randomized studies report improvements in attention and reading metrics at low intranasal doses. Western replication: none.

Acute cognitive effects in healthy adults. Smaller human studies at standard research doses (300–600 µg) show EEG changes consistent with increased attentional tone and measurable improvements on vigilance tasks within 30–90 minutes. These are consistent with the proposed neurotrophic-acute overlap mechanism.

Evidence tier: Tier 3 for most indications by Western standards — published human data exists but is concentrated in one research tradition with limited independent replication. By Russian standards, semax is closer to Tier 1 for stroke and Tier 2 for cognitive indications. Reasonable readers can weight this differently; we flag it explicitly rather than paper over the gap.

Typical dosing protocols

In Russian clinical use, intranasal semax is delivered as a 0.1% or 1% solution (commonly sold as "Semax 0.1%" or "Semax 1%"). Each drop of a 0.1% solution delivers approximately 50 µg of peptide; a 1% solution delivers approximately 500 µg per drop.

Common off-label adult protocols seen in English-speaking community reports:

• Acute cognitive use: 300–600 µg (6–12 drops of 0.1%) split into both nostrils, morning.
• Stroke recovery (Russian clinical): 300–1200 µg/day in divided doses for 10 days.
• Long-term low-dose maintenance: 50–200 µg daily or every other day.

These are protocols, not prescriptions. Quality varies dramatically between vendors; impurity data in third-party testing of research-grade semax is poor.

What are the side effects?

Reported side effects from Russian clinical trials and community protocol logs:

• Local nasal irritation, burning, or mild rhinorrhea (common, dose-dependent).
• Headache (uncommon, typically mild).
• Sleep disruption when dosed late in the day (common at higher doses).
• Emotional flatness or anhedonia at very high chronic doses (anecdotal, not characterized in trials).

Serious adverse events are rare in the published record. The safety profile reflects both the relatively short history of high-dose Western use and the natural underreporting of negative anecdotes on forums.

Who should NOT use intranasal semax?

• Pregnancy and lactation: no safety data.
• Active nasal pathology (polyps, septal ulceration, post-surgical): delivery will be poor and irritation worse.
• MAOIs and strong serotonergic agents: theoretical interaction via modulation of monoaminergic systems; no documented cases but mechanism is non-zero.
• Anyone using it in lieu of treatment for an acute stroke or serious psychiatric condition. Semax is not a substitute for emergency or specialist care.

Limitations of the evidence base

Four specific gaps readers should know about:

1. Western peer-reviewed replication is limited. Most positive trials are from one research group in one country.
2. Trials predating 2010 rarely registered protocols in advance; reporting bias cannot be ruled out.
3. Dose-response relationships are not cleanly characterized outside the 300–1200 µg/day range.
4. Long-term safety data (5+ years continuous use) does not exist in any published record.

Non-responder reports

In aggregated community protocol logs (pending our Experience Hub rollout), an estimated 20–25% of first-time users report no noticeable acute cognitive effect at standard doses. Common reasons, where identified: (1) technique — anterior nasal deposition rather than olfactory deposition, (2) vendor quality — peptide purity below 90%, (3) expectation mismatch — acute effects are subtle and task-dependent rather than stimulant-like.

FAQs

Is semax legal in the US? Semax is not FDA-approved. It is not scheduled under the Controlled Substances Act. Import as "research chemical" exists in a gray zone; compounding pharmacy access is possible in limited cases. State-level rules vary. This is not legal advice; see our state-by-state legal guides.

Can I take semax orally? You can, but the vast majority is degraded in the GI tract before absorption. Oral bioavailability is effectively zero for the free peptide. Reports of "oral semax" achieving cognitive effects likely reflect either sublingual absorption (partial) or placebo.

What's the difference between semax and N-Acetyl Semax? N-Acetyl Semax and N-Acetyl Semax Amidate are acetylated variants with extended half-life and improved stability in aqueous solution. Empirically, users report longer-duration but less acute intensity. Published pharmacokinetic comparisons in humans are sparse.

Is semax the same as selank? No. Selank (TKPRPGP) is a separate heptapeptide, also from the same Russian research tradition, with anxiolytic rather than pro-attentional primary effects. They are frequently compared but are chemically and pharmacologically distinct.

Sources

1. Ashmarin IP, et al. "Design and biological activity of a new ACTH analog — semax — in the neurological clinic." Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34.
2. Gusev EI, Skvortsova VI, et al. "Efficacy of semax in acute period of ischemic stroke." Zh Nevrol Psikhiatr Im S S Korsakova. 2005; supplement 16.
3. Dolotov OV, et al. "Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents." Neurosci Lett. 2006;392(1-2):131-135.
4. Shevchenko KV, et al. "Pharmacokinetics of semax after intranasal administration in rats." Bull Exp Biol Med. 2006;142(6):697-699.
5. Medvedeva EV, et al. "Semax modulates synaptic plasticity and neurotrophic factor expression." Neurochem Int. 2017;108:326-331.
6. Kumar NN, et al. "Delivery of peptides via the nose-to-brain route." Adv Drug Deliv Rev. 2018;135:131-145.
7. Lochhead JJ, Thorne RG. "Intranasal delivery of biologics to the central nervous system." Adv Drug Deliv Rev. 2012;64(7):614-628.